Skip to main content
Journal cover image

Cabozantinib in genitourinary malignancies.

Publication ,  Journal Article
Zhang, T; Park, SE; Hong, C; George, DJ
Published in: Future Oncol
April 2017

Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most activity in advanced renal cell carcinoma; the METEOR study compared cabozantinib to everolimus and showed clinically and statistically significant improvements in both progression-free survival and overall survival. Herein, we review the development of cabozantinib in the genitourinary malignancies of renal cell carcinoma, prostate adenocarcinoma and urothelial carcinoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Future Oncol

DOI

EISSN

1744-8301

Publication Date

April 2017

Volume

13

Issue

8

Start / End Page

755 / 765

Location

England

Related Subject Headings

  • Urogenital Neoplasms
  • Treatment Outcome
  • Pyridines
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Grading
  • Humans
  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase II as Topic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, T., Park, S. E., Hong, C., & George, D. J. (2017). Cabozantinib in genitourinary malignancies. Future Oncol, 13(8), 755–765. https://doi.org/10.2217/fon-2016-0358
Zhang, Tian, Se Eun Park, Cierra Hong, and Daniel J. George. “Cabozantinib in genitourinary malignancies.Future Oncol 13, no. 8 (April 2017): 755–65. https://doi.org/10.2217/fon-2016-0358.
Zhang T, Park SE, Hong C, George DJ. Cabozantinib in genitourinary malignancies. Future Oncol. 2017 Apr;13(8):755–65.
Zhang, Tian, et al. “Cabozantinib in genitourinary malignancies.Future Oncol, vol. 13, no. 8, Apr. 2017, pp. 755–65. Pubmed, doi:10.2217/fon-2016-0358.
Zhang T, Park SE, Hong C, George DJ. Cabozantinib in genitourinary malignancies. Future Oncol. 2017 Apr;13(8):755–765.
Journal cover image

Published In

Future Oncol

DOI

EISSN

1744-8301

Publication Date

April 2017

Volume

13

Issue

8

Start / End Page

755 / 765

Location

England

Related Subject Headings

  • Urogenital Neoplasms
  • Treatment Outcome
  • Pyridines
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoplasm Grading
  • Humans
  • Clinical Trials, Phase III as Topic
  • Clinical Trials, Phase II as Topic